Clinical Trials Logo

Grade II Meningioma clinical trials

View clinical trials related to Grade II Meningioma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04278118 Recruiting - Clinical trials for Intracranial Neoplasm

Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study

HiPPI
Start date: February 18, 2020
Phase: N/A
Study type: Interventional

This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells. A shorter duration of radiation treatment may avoid some of the delayed side effects of radiation while providing a more convenient treatment and reducing costs.

NCT ID: NCT03180268 Recruiting - Clinical trials for Intracranial Meningioma

Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Start date: June 14, 2017
Phase: Phase 3
Study type: Interventional

This randomized phase III trial studies how well radiation therapy works compared with observation in treating patients with newly diagnosed grade II meningioma that has been completely removed by surgery. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors.

NCT ID: NCT02847559 Recruiting - Clinical trials for Recurrent Meningioma

Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma

Start date: August 2016
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas. Bevacizumab is considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study drug is a medication that blocks the growth of new blood vessels. It is thought that the study drug may interfere with the growth of new blood vessels and therefore might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Optune is also considered investigational because the US FDA has not approved its use for the treatment of meningiomas. Optune is a device that the patient will wear and use for at least 18 hours of each day. It delivers alternating electrical current to the patient's brain tumor and by doing so interrupts a process called mitosis. Mitosis needs to occur in order for cell division to occur and allows tumors to grow. By slowing this process, we hypothesize that meningioma growth may also be slowed.